Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
Loke, Justin Upasani, Vinit Gaskell, Charlotte Fox, Sonia Fletcher, Rachel Thomas, Catherine Hopkins, Louise Kumari, Anita Tang, Tina Yafai, Emily
Loke, Justin
Upasani, Vinit
Gaskell, Charlotte
Fox, Sonia
Fletcher, Rachel
Thomas, Catherine
Hopkins, Louise
Kumari, Anita
Tang, Tina
Yafai, Emily
Abstract
Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.
MIDER Authors
Citations
Altmetric:
Date
2023-06-12
Type
Article
Subject
Citation
Br J Haematol . 2023 Aug;202(3):498-503
Journal / Source Title
British Journal of Haematology
DOI
10.1111/bjh.18894
PMID
37303189
Publisher
Wiley